DALLAS, Oct. 28, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring biopharmaceutical company Incyte Corp. (Nasdaq:INCY). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Incyte Corp. (Nasdaq:INCY) should be of particular interest to comparable companies: Gilead Sciences Inc. (Nasdaq:GILD), Biogen Idec Inc. (Nasdaq:BIIB), Genzyme Corp. (Nasdaq:GENZ) and Amgen Inc. (Nasdaq:AMGN).
The full report is available at: http://www.stockpreacher.com/n/INCY
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher
Incyte Corporation (INCY) is a drug discovery and development company focused on developing small molecule drugs to treat serious unmet medical needs. The Company has a pipeline with programs in oncology, inflammation and diabetes. INCY's pipeline includes compounds in various stages of development in the areas of oncology, inflammation, diabetes and human immunodeficiency virus (HIV).
Message Board Search for INCY: http://www.boardcentral.com/boards/INCY
In the report, the analyst notes:
"INCY earlier this year announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a pivotal phase III trial for its lead JAK1/JAK2 Inhibitor, INCB18424, in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF).
"INCY last month announced positive clinical trial results for a topical formulation of its lead janus kinase (JAK) inhibitor, INCB18424, in psoriasis. These results were obtained from a multi-center three-month phase II(b) trial comparing three once-daily doses of topical INCB18424 to vehicle in 200 patients with mild-to-moderate psoriasis. In the trial patients treated with INCB18424 had a statistically significant improvement over placebo in the reduction in total lesion score (erythema + scaling + thickness), which was the primary efficacy endpoint of the trial."
To read the entire report visit: http://www.stockpreacher.com/n/INCY
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.